NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
CompletedN/A
Sponsor: Hoffmann-La Roche
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: MabThera
Countries: South Korea
This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.
Eligibility overview
Sex: ALL
Age: 19 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: * Participants administered with MabThera subcutaneously within the approved indication in Korea * Participants previously untreated with MabThera subcutaneously Inclusion Criteria for NHL participants for MabThera subcutaneously 1400mg: * Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants * Previously untreated FL participants in combination with chemotherapy * Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy. * Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy Inclusion Criteria for CLL participants for MabThera subcutaneously 1600mg: \- Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy Exclusion Criteria: * Pregnant or breastfeeding women * Participants who are out of locally approved indications, dosage, and administration including medication error * Contraindication in use by locally approved indications, dosage, and administration
Locations (25)
- Bucheon-si, South Korea
- Busan, South Korea
- Busan, South Korea
- Daegu, South Korea
- Daegu, South Korea
- Daegu, South Korea
- Daejeon, South Korea
- Gyeonggi-do, South Korea
- Gyeonggi-do, South Korea
- Gyeonggi-do, South Korea
- Gyeongsangnam-do, South Korea
- Incheon, South Korea
- Jeollanam-do, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Ulsan, South Korea